Q-omics provides the consensus-scored CCDC27 profile across patient tissues and cancer cell-line models. CCDC27 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCDC27 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, CCDC27 RNA expression shows 17,590 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, BRCA, and THYM as cancer lineages where CCDC27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC27 survival associations across molecular data types. CCDC27 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC27 RNA expression–survival associations across cancer types. High CCDC27 expression shows unfavorable associations in ACC, UCEC, LIHC, KIRP and THCA, but favorable associations in UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCDC27 RNA expression.
This table summarizes CCDC27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC27 shows lower tumor expression in BRCA, THCA, BLCA and PRAD and higher tumor expression in LUSC and KIRC. The BRCA box plot shows higher CCDC27 RNA expression in normal versus tumor tissue (log2 FC = −0.195, t-test p < 0.001).
This table shows molecular features associated with CCDC27 in patient tissues and cancer cell lines. In patient samples, CCDC27 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
